Your browser doesn't support javascript.
loading
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka, Satoshi; Zhang, Wu; Cao, Shu; Hanna, Diana L; Sunakawa, Yu; Sebio, Ana; Ueno, Masashi; Yang, Dongyun; Ning, Yan; Parekh, Anish; Okazaki, Satoshi; Berger, Martin D; Ichikawa, Wataru; Mizunuma, Nobuyuki; Lenz, Heinz-Josef.
Affiliation
  • Matsusaka S; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Zhang W; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Cao S; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Hanna DL; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Sunakawa Y; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Sebio A; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Ueno M; Department of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan.
  • Yang D; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Ning Y; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Parekh A; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Okazaki S; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Berger MD; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Ichikawa W; Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Mizunuma N; Department of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan.
  • Lenz HJ; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California. lenz@usc.edu.
Mol Cancer Ther ; 15(6): 1405-11, 2016 06.
Article in En | MEDLINE | ID: mdl-26983880
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Organoplatinum Compounds / Nuclear Proteins / Colorectal Neoplasms / Polymorphism, Single Nucleotide / Twist-Related Protein 1 / Bevacizumab Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2016 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Organoplatinum Compounds / Nuclear Proteins / Colorectal Neoplasms / Polymorphism, Single Nucleotide / Twist-Related Protein 1 / Bevacizumab Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2016 Type: Article